Valuation: TOUE BIOPAR

Market Cap 1.24B 1.08B 999M 927M 1.76B 118B 1.78B 11.95B 4.65B 57.96B 4.65B 4.55B 201B P/E 2023
-2.95x
P/E 2024 -7.02x
Enterprise Value 980M 858M 790M 734M 1.39B 93.46B 1.41B 9.46B 3.68B 45.88B 3.68B 3.6B 159B EV / Sales 2023
-
EV / Sales 2024 -
Free-Float
-
Yield 2023 *
-
Yield 2024 -
1 year 15.94
Extreme 15.94
48.27
3 years 9.18
Extreme 9.18
48.31
5 years 9.18
Extreme 9.18
48.31
10 years 9.18
Extreme 9.18
48.31
Date Insider Type Main position Quantity % Market Cap.
25-10-27Tender

Chief Technology Officer

203,927 0.7944%
25-10-27OtherCompany 24,030,382 93.6139%
25-10-27Tender

General Counsel

252,504 0.9837%

Financials

2023 2024
Net sales - -
Net income -42.12M -36.89M -33.98M -31.54M -59.89M -4.02B -60.7M -407M -158M -1.97B -158M -155M -6.84B -73.21M -64.12M -59.06M -54.82M -104M -6.98B -106M -707M -275M -3.43B -275M -269M -11.88B
Net Debt -203M -177M -163M -152M -288M -19.32B -292M -1.96B -761M -9.48B -761M -744M -32.88B -258M -226M -208M -193M -367M -24.62B -372M -2.49B -970M -12.08B -969M -948M -41.89B
Logo TOUE BIOPAR
Tourmaline Bio, Inc. is a late-stage clinical biotechnology company. The Company is focused on developing transformative medicines that improve the lives of patients with life-altering immune and inflammatory diseases. The Company’s initial product candidate is TOUR006, a fully human monoclonal antibody that selectively binds to interleukin-6 (IL-6), a key proinflammatory cytokine involved in the pathogenesis of many autoimmune and inflammatory disorders. TOUR006 is a long-acting anti-IL-6 antibody which has properties, including a high binding affinity to IL-6, long half-life, and low observed immunogenicity. It is also developing TOUR006 in thyroid eye disease (TED) and atherosclerotic cardiovascular disease (ASCVD) as its first two indications, with additional diseases under consideration. It is focused on two strategic paths for TOUR006, the first of which it refers to as FcRn+. Its second strategic path is cardiovascular inflammation.
Employees
77
Sector
-
Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
  1. Stock Market
  2. Stocks
  3. TRML Stock